Corcept Therapeutics Incorporated (NASDAQ:CORT) is scheduled to post its quarterly earnings results after the market closes on Monday, July 31st. Analysts expect Corcept Therapeutics to post earnings of $0.07 per share for the quarter.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Monday, May 1st. The biotechnology company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. Corcept Therapeutics had a net margin of 13.51% and a return on equity of 33.97%. The firm had revenue of $27.60 million during the quarter, compared to analyst estimates of $25.53 million. The business’s quarterly revenue was up 71.9% compared to the same quarter last year. On average, analysts expect Corcept Therapeutics to post $0.26 EPS for the current fiscal year and $0.52 EPS for the next fiscal year.

Shares of Corcept Therapeutics Incorporated (CORT) opened at 12.97 on Monday. The firm’s 50-day moving average is $11.86 and its 200-day moving average is $10.06. Corcept Therapeutics Incorporated has a 12-month low of $5.24 and a 12-month high of $13.25. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of 118.99 and a beta of 2.05.

CORT has been the subject of several analyst reports. Ladenburg Thalmann Financial Services set a $20.00 price target on shares of Corcept Therapeutics and gave the company a “buy” rating in a research note on Tuesday, July 18th. Zacks Investment Research raised shares of Corcept Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. BidaskClub raised shares of Corcept Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. TheStreet raised shares of Corcept Therapeutics from a “c+” rating to a “b” rating in a research note on Monday, May 22nd. Finally, Piper Jaffray Companies set a $18.00 price target on shares of Corcept Therapeutics and gave the company a “buy” rating in a research note on Monday, May 15th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $14.20.

WARNING: “Corcept Therapeutics Incorporated (CORT) to Release Earnings on Monday” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/24/corcept-therapeutics-incorporated-cort-to-release-earnings-on-monday.html.

In related news, Director David L. Mahoney sold 23,006 shares of Corcept Therapeutics stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $12.50, for a total transaction of $287,575.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David L. Mahoney sold 6,994 shares of Corcept Therapeutics stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $12.50, for a total transaction of $87,425.00. The disclosure for this sale can be found here. Insiders have sold 42,601 shares of company stock valued at $532,513 in the last ninety days. Insiders own 19.20% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Earnings History for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.